Trial Profile
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Study to Evaluate the Safety and Efficacy of CT1812 in Subjects With Mild to Moderate Alzheimer's Disease
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 24 Apr 2024
Price :
$35
*
At a glance
- Drugs CT 1812 (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics; Therapeutic Use
- Acronyms SHINE
- Sponsors Cognition Therapeutics
- 22 Apr 2024 According to a Cognition Therapeutics media release, company provided a recap of the virtual KOL event hosted on April 12, 2024 featuring Martin J. Sadowski, MD, PhD, DSci of the NYU School of Medicine; Anton Porsteinsson, MD of the University of Rochester Alzheimer's Disease Care, Research and Education Program
- 01 Apr 2024 According to a Cognition Therapeutics media release, today announced it will host a virtual KOL event on Friday, April 12, 2024 from 8:00 AM to 9:30 AM ET. The KOLs and Cognition management will discuss CT1812 which includes the Phase 2 START Study in people with early stage disease.
- 26 Mar 2024 According to a Cognition Therapeutics media release, enrollment completed of 153 adults.